小剂量阿立哌唑作为增效剂治疗强迫症的疗效

目的：探讨小剂量阿立哌唑作为增效剂治疗强迫症的疗效与不良反应。方法将99例强迫症患者按随机数字表法分为3组：A组33例口服盐酸帕罗西汀40 mg·d-1，B组32例口服盐酸帕罗西汀40 mg·d-1＋阿立哌唑2.5 mg·d-1, C组34例口服盐酸帕罗西汀40 mg·d-1＋阿立哌唑5 mg·d-1。采用耶鲁布朗强迫量表（Y-BOCS）评定3组临床疗效,并采用副反应评定量表（TESS）对3组治疗期间的不良反应情况进行评价。结果治愈率A、B、C 组分别为15.1%、28.1%、29.4%，总有效率A、B、C组分别为65.4%、68.7%、64.7%，B、C组治愈率、总有效率均显著高于A组（P〈0.05）；治疗期间3组不良反应发生率比较差异均无统计学意义（P＞0．05）。结论小剂量阿立哌唑作为增效剂治疗强迫症具有明显的增效作用，且无严重不良反应发生。

Low-Dose Aripiprazole as Synergistic Agent for Obsessive Compulsive Disorder

Objective To investigate the efficacy and adverse reactions of low-dose aripiprazole as synergistic agent in the treatment of obsessive compulsive disorder. Methods Ninety-nine patients with obsessive compulsive disorder were randomly treated with oral paroxetine hydrochloride 40 rag＂ d-1 alone （group A,n=33） or in combination with aripiprazole 2.5 mg·d-1（group B,n=32）or 5 mg·d-1（group C, n=34）. Clinical efficacy and adverse reactions were assessed using Yale-Brown Obsessive Compulsive Scale （Y-BOCS）and Treatment Emergent Symptom Scale （TESS）,respectively. Results The cure rate was 15.1%, 28.1% and 29.4% in group A, B and C, respectively. The total effective rate was 65.4%, 68.7% and 64.7% in group A, B and C, respectively. Compared with group A, both cure rate and total effective rate significantly increased in group B and C （P〈0.05）. There were no significant differences in the incidence of adverse reactions among the three groups（P〉0.05）. Conclusion Low-dose aripiprazole exerts a significant synergistic effect and does not cause serious adverse reactions in the treatment of obsessive compulsive disorder.